Ironwood Pharma (IRWD) Tops Q4 EPS by 7c

Ironwood Pharmaceuticals (IRWD) Costs Increase to Offset Revenue Upside - Wedbush

Wedbush analyst, David Nierengarten, is cautious on Ironwood Pharmaceuticals (NASDAQ: IRWD) as operating leverage remains elusive. No change to Neutral rating but the PT drops to $9 from $10.

IRWD reported 4Q15 Linzess US net sales of $129.7M, in-line with our estimate of $132M. Symphony Health Solutions recorded sales of $199.6M, implying a g-t-n of 35%, in line with last quarter. IRWD reported more than 585k scripts were filled in Q4,... More

Mizuho Securities Reiterates Buy Following Ironwood Pharma's (IRWD) Strong 4Q Results

Mizuho Securities reiterated a Buy rating and $15.00 price target on Ironwood Pharmaceuticals (NASDAQ: IRWD) following the company's 4Q earnings report. IRWD reported revenues of $53.3M, beating consensus estimates of $44.5M. EPS loss of ($0.09) also came in ahead of consensus' ($0.17). Management also issued... More

BTIG Sees Opportunity in Ironwood Pharma (IRWD) Weakness; Affirms at 'Buy'

BTIG affirms its Buy rating and $15 price target on Ironwood Pharmaceuticals (Nasdaq: IRWD) following IRWD's Q4 results issued Thursday night.

Analyst Timothy Chiang noted that IRWD's Q4 included $53.3 million of collaboration revenue (vs. our $44 million estimate) and a loss per share of... More

Leerink Partners Remains Sidelined After Ironwood Pharma's (IRWD) 4Q

Leerink Partners reiterated a Market Perform rating on Ironwood Pharmaceuticals (NASDAQ: IRWD), and cut the price target to $11.00 (from $12.00), following the company's 4Q earnings release. IRWD reported 4Q Linzess sales of ~$130m, coming in slightly below Leerink's estimate of ~$131m. Collaborative revenues of ~$53m were in line with estimates. IRWD plans to progress IW-1701 and IW-1973 into... More